Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
July 25, 2022 16:05 ET
|
Allakos Inc.
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and...
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
May 06, 2022 16:05 ET
|
Allakos Inc.
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:05 ET
|
Allakos Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic...
Allakos to Host Investor Day on February 15
February 01, 2022 08:00 ET
|
Allakos Inc.
– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a...
Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
December 21, 2021 19:15 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of...
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
November 30, 2021 07:00 ET
|
Allakos Inc.
– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated –– Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 –– Phase 2 Asthma trial of...
Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
November 08, 2021 16:05 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast...
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation
October 25, 2021 08:00 ET
|
Allakos Inc.
– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis...
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting
October 24, 2021 15:35 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast...
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
August 09, 2021 16:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast...